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A B S T R A C T
Background: Methylnaltrexone, a selective peripheral acting mu-opioid receptor antago-
nist, alleviates the constipating effects of opioids without affecting centrally mediated an-
algesia.
Objectives: To assess the effect of subcutaneous (SC) methylnaltrexone injection on pa-
tient-reported constipation symptoms and pain scores.
Methods: A total of 469 subjects on opioids for chronic non-malignant pain with opioid-
induced constipation were randomized to methylnaltrexone SC with once daily (QD) or
every other day (QOD) dosing or placebo for 4 weeks. Constipation symptoms and pain were
assessed using the patient assessment of constipation–symptoms (PAC-SYM) questionnaire
and a 11-point scale, respectively, at baseline, Day 14 and Day 28. Change from baseline in
PAC-SYM and pain scores were compared between methylnaltrexone and placebo arms at
Day 28 using analysis of covariance, with treatment group as factor and baseline score as
covariate.
Results: A majority of patients were women (60%), average age was 49 years old, and
back pain (60%) was the primary pain condition. At Day 28, the methylnaltrexone SC QD
group showed a significant improvement over placebo for rectal symptoms (0.56 vs.
– 0.30; P  0.05), stool symptoms (0.76 vs. – 0.43; P  0.001) and global scores (0.62 vs.
– 0.37; P  0.001). Improvement in stool symptoms (0.69 vs.0.43; P  0.05) and the
global scores (0.52 vs. –0.37; P 0.05) were significantly greater than placebo in the meth-
ylnaltrexone QOD group. Differences in change from baseline in abdominal symptoms and
pain scores between the methylnaltrexone SC QD or QOD dosing arms and placebo were not
significant.
Conclusion: The results of our study indicate significant improvement in constipation
symptoms with methylnaltrexone QD or QOD dosing compared to placebo without a signif-
icant effect on pain scores.
Copyright © 2011, International Society for Pharmacoeconomics and Outcomes Research(ISPOR). Published by Elsevier Inc.
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178 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 7 7 – 1 8 3ntroduction
pioid therapy plays a key role in the management of chronic
ain. Opioids have been widely used to treat malignant pain
nd their use to manage nonmalignant pain has also been
ncreasing in recent years [1]. Despite proven analgesic effi-
acy in the management of pain, opioid therapy is frequently
omplicated by side effects [2]. Constipation is a common and
npleasant side effect associated with opioid therapy with
pproximately 40% of patients using opioids for non-malig-
ant pain, reporting constipations symptoms [2]. Unlike most
ther common opioid side effects, opioid-induced constipa-
ion (OIC) is often persistent and can lead to serious medical
onsequences such as bowel obstruction or fecal impaction
1,3]. Severe and persistent constipation is one of the most
ommon reasons for patient discontinuation of opioid analge-
ics, thus leading to a negative effect on pain management
nd quality of life [4]. Opioids impair normal bowel function
rimarily by binding to intestinal mu-opioid receptors and in-
errupting the coordinated rhythmic contractions required for
ntestinal motility [5]. Opioids can also alter intestinal fluid
ecretion by a direct effect on the enteric nervous system [6].
elective blockade of the peripheral receptors might relieve
onstipation without compromising centrally mediated ef-
ects of opioid analgesia or precipitating withdrawal [7].
Currently, there is no approved drug indicated for the treat-
ent of OIC in the population of patients receiving opioid
herapy for chronic, non-malignant pain. Methylnaltrexone
N-methylnaltrexone bromide, RELISTOR [Progenics Pharma-
euticals, Tarrytown, NY, USA]), a quaternary derivative of
altrexone, has been approved as a subcutaneous (SC) injec-
ion for the treatment of OIC in patients with advanced illness
ho are receiving palliative care, when response to laxative
herapy has not been sufficient [8]. Unlike the uncharged sys-
emic opioid antagonists naloxone and naltrexone, a charged
ntagonist like methylnaltrexone has restricted ability to
ross the blood-brain barrier because of its polarity and low
ipid solubility [9,10]. As a result, methylnaltrexone antago-
izes the peripherally located opioid receptors in the gastro-
ntestinal tract, thus reducing OIC without precipitating with-
rawal symptoms or negatively affecting or reversing the
nalgesic effects of opioids [9,11–13].
A randomized, placebo-controlled, phase 3 study was de-
igned to determine the efficacy and safety of SC methylnal-
rexone compared with placebo in relieving OIC in patients
eceiving opioid therapy for chronic non-malignant pain. Two
o-primary end points were defined during the double-blind
eriod: 1) the proportion of subjects having a rescue-free
owel movement (RFBM) within 4 hours of the first dose, and
) the percentage of active injections resulting in any RFBM
ithin 4 hours [14]. In addition, data were collected on patient-
eported pain scores, constipation symptoms, and quality of
ife using validated instruments.
Here we report the effect of methylnaltrexone SC on pa-
ient-reported constipation symptoms and pain intensity
cores over a 4-week double-blind period in subjects experi-
ncing constipation because they are receiving opioids for
hronic non-malignant pain. aethods
double-blind, randomized, parallel-group, placebo-con-
rolled, phase 3 study was conducted to evaluate the safety,
fficacy and tolerability of SC methylnaltrexone versus pla-
ebo in subjects with chronic non-malignant pain who have
IC. Subjects were eligible if they had a history of chronic
on-malignant pain for at least 2 months’ duration, an opioid
ose of equal to or greater than 50 mg oral morphine equiva-
ents per day for at least 2 weeks, a history of constipation due
o opioid use for at least 1 month, and fewer than 3 RFBMs per
eek before the screening visit. Eligible subjects who signed
n informed consent form entered a 14-day ( 2-day visit win-
ow) screening period, during which objective evidence of
onstipation was assessed. Constipation during the screening
eriod was defined as fewer than 3 RFBMs per week (no laxa-
ive use within 24 hours prior to any bowel movement) that
ere associated with one or more of the following: a) a Bristol
tool Form Scale score [15] of 1 or 2 for at least 25% of the bowel
ovements; b) straining during at least 25% of the bowel
ovements; c) a sensation of incomplete evacuation after at
east 25% of the bowel movements. Exclusion criteria included
regnant or breast feeding women, use of methylnaltrexone
ithin 4 weeks of administration of the first dose of test arti-
le, non-compliance with subject diary completion, and use of
escue laxative. Subjects who remained eligible at the baseline
isit were randomly assigned to receive daily injections con-
aining placebo, methylnaltrexone 12 mg once daily (QD), or
ethylnaltrexone 12 mg every other day (QOD) in a 1:1:1 allo-
ation ratio for 28 days. If subjects did not have a bowel move-
ent for 3 consecutive days during the study, they were per-
itted to use bisacodyl tablets, which were provided by the
nvestigator.
Beginning at the screening visit, eligible subjects reported
he number of bowel movements per day including the time of
ach bowel movement by using an interactive voice response
ystem (IVRS) via telephone. For each bowel movement, sub-
ects assessed consistency, straining, and a sensation of com-
lete evacuation. Also reported were rescue laxative use (in-
luding whether rescue medication was taken and the time of
dministration), doses of opioid medication, and pain inten-
ity during the past 24 hours. At baseline and on Days 14 and
8, average pain intensity ratings were recorded on a scale of 0
no pain) to 10 (worst possible pain) [16]. Safety evaluations
ncluded monitoring of adverse events from the screening
isit through 14 days after the last dose of test article. Con-
omitant treatment including use of opioids and rescue laxa-
ives from the screening visit through the follow-up period
as recorded. At office visits, height, weight, and vital sign
easurements were determined and physical examinations
nd laboratory evaluations were performed.
In addition, patient-reported constipation symptoms were
ssessed at baseline, Day 14, and Day 28 using the patient
ssessment of constipation symptoms (PAC-SYM) question-
aire. The PAC-SYM questionnaire is a 12-item survey that
easures constipation symptoms and associated severity
cross three domains: stool symptoms, rectal symptoms, and







































































179V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 7 7 – 1 8 317]. Score changes on the PAC-SYM global score of approxi-
ately half a point have been reported to correspond to min-
mal clinical improvement, and changes of about 1 point cor-
espond to moderate clinical improvement [17].
The PAC-SYM has been demonstrated and documented to
e a sensitive, reliable, valid, and responsive measure for
onitoring the symptoms of OIC [18]. Symptom items are
ated on a 5-point Likert severity scale. Item values are scored
rom 0 to 4, with 0 indicating absence of symptom, 1mild, 2
moderate, 3  severe, and 4  very severe indicating the
orst severity of that symptom.
For each of the subscales, scores for the nonmissing items
ithin the subscale are summed and divided by the total
umber of nonmissing items for that subscale (range, 0–4).
or total instrument (Global) score, the scores of nonmissing
tems within the instrument are summed and divided by the
otal number of nonmissing items (total score range, 0–4).
hange from baseline at Day 14 and Day 28 (end of the double-
lind period) in pain, subscale, and total PAC-SYM scores were
nalyzed using analysis of covariance (ANCOVA) with treat-
ent as a factor and baseline score as a covariate based on the
ast observation carry-forward (LOCF) data. As part of sensi-
ivity analyses, the change from baseline analyses were rerun
ith the observed cases data. The proportion of patients
howing minimal and moderate clinical improvement based
n the PAC-SYM total score was calculated.
The study was conducted in accordance with the ethical prin-
iples of the Declaration of Helsinki and was consistent with the
uidelines for Good Clinical Practice. The institutional review
oards or independent ethics committees of the participating
edical centers approved the study protocol and informed con-
ent document. All patients gave written informed consent be-
ore any study-related tests were performed.
esults
atients: A total of 469 patients with chronic nonmalignant
ain and OIC were randomized, of which 460 received at least
Table 1 – Demographic and baseline clinical characteristics
Characteristic Methylnaltrexone
12 mg QD treatment
(n150)
Age, mean (SD) 47.99 (10.74)
Female gender, N (%) 93 (62.0)






Primary pain condition N (%)
Back 96 (64.0)
Morphine equivalent dose (mg)
Mean (SD) 214 (157)
All values are means (SD), unless otherwise noted, for all patients.
mITT, modified intent-to-treat; QD, once daily; QOD, every other dayne dose of study treatment. The modified intent-to-treat fmITT) population of 460 patients was analyzed for constipa-
ion symptoms. There were 388 subjects (84%) who completed
he double-blind portion of the trial. Demographic and base-
ine disease characteristics of the study participants are
hown in Table 1.
A majority of the patients in the study were women (60%)
nd white (90%); the average age was 49 years old and back
ain (60%) was reported as the primary pain condition. The
ean daily baseline oral morphine-equivalent opioid dose
as 222 mg.
Descriptive statistics for the PAC-SYM and pain intensity
cores at baseline are presented in Table 2. At baseline, the
verage scores for abdominal symptoms, rectal symptoms,
nd the PAC-SYM global score were in the mild to moderate
everity range, whereas the average scores for stool symp-
oms were in the moderate to severe range across all treat-
ent groups.
PAC-SYM global score and pain intensity score mean val-
es at baseline were similar for the three treatment arms. On
ay 14, data were missing for approximately 12% of cases in
reatment groups and 5% of cases in the placebo group. For PAC-
YM global score on Day 14, the methylnaltrexone 12 mg QD
roup showed an improvement of 0.56 (29.5%) from baseline,
ompared with an improvement of 0.32 (17.8%) for placebo (be-
ween-group difference P 0.001). At Day 14, the methylnaltrex-
ne 12 mg QOD group showed an improvement of 0.42 (22.7%)
rom baseline in the PAC-SYM global score, which was not sta-
istically significant compared with placebo (Table 3).
On Day 14, rectal symptoms showed statistically signifi-
ant improvements compared with placebo in the methylnal-
rexone QD group (P  0.001) and the methylnaltrexone QOD
roup (P  0.05). Similarly, for stool symptoms, statistically
ignificant improvements compared with placebo were de-
ected in the methylnaltrexone QD group (P  0.001) and the
ethylnaltrexone QOD group (P 0.05). For abdominal symp-
oms, no statistically significant differences were found in the
hange from baseline scores between the methylnaltrexone QD
nd QOD dosing arms and placebo (Table 3). Similarly, for pain
ntensity scores no statistically significant differences were
TT population).
Methylnaltrexone Placebo
(n162)12 mg QOD treatment
(n148)
48.64 (11.05) 49.69 (10.77)
85 (57.4) 99 (61.1)
85.1 (21.9) 87.2 (26.3)
133 (89.9) 141 (87.0)
10 (6.8) 15 (9.3)
1 (0.7) 1 (0.6)
4 (2.7) 5 (3.1)
83 (56.1) 99 (61.1)
225 (205) 225 (216)





































180 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 7 7 – 1 8 3altrexone QD and QOD dosing arms and placebo (Table 3). On
ay 14, proportion of patients meeting the minimal clinical im-
rovement criteria of 0.5 point improvement from baseline on
he global score was 48% of patients in the methylnaltrexone QD
rm, 39% in the methylnaltrexone QOD arm, and 38% in the
lacebo arm. Similarly 25% of patients in the methylnaltrexone
D arm, 17% in the methylnaltrexone QOD arm, and 14% in the
lacebo demonstrated moderate clinical improvement with 1
oint improvement on the global score.
On Day 28, data were missing for approximately 16% to 18%
f cases in treatment groups and 11% of cases in the placebo
roup. At the end of the double-blind period (Day 28), the
ethylnaltrexone 12 mg QD group showed an improvement
f 0.62 (32.6%) from baseline in PAC-SYM global mean scores,
ompared with an improvement of 0.37 (20.6%) for placebo
between-group difference P  0.001). At Day 28, the methyl-
altrexone 12 mg QOD group showed an improvement of 0.52
28.1%) from baseline, which was significantly greater than
hat shown by the placebo group (between-group difference





Abdominal symptoms 1.77 (0.87)
Rectal symptoms 1.45 (1.01)
Stool symptoms 2.26 (0.95)
Global PAC-SYM score 1.90 (0.77)
Pain scores† 6.23 (1.93)
PAC-SYM, patient assessment of constipation–symptoms; QD, once d
* Reported values of raw scores across the 3 treatment groups range
† Pain was rated on a scale of 0 (no pain) to 10 (worst possible pain).
Table 3 – PAC-SYM and pain scores and change from base
Construct Treatment N
Me
Abdominal symptoms Methylnaltrexone 12 mg QD 150 1.3
Methylnaltrexone 12 mg QOD 148 1.4
Placebo 162 1.2
Rectal symptoms Methylnaltrexone 12 mg QD 150 0.9
Methylnaltrexone 12 mg QOD 148 0.9
Placebo 162 1.0
Stool symptoms Methylnaltrexone 12 mg QD 150 1.5
Methylnaltrexone 12 mg QOD 148 1.7
Placebo 162 1.9
Global score Methylnaltrexone 12 mg QD 150 1.3
Methylnaltrexone 12 mg QOD 148 1.4
Placebo 162 1.5
Pain scores Methylnaltrexone 12 mg QD 149 6.2
Methylnaltrexone 12 mg QOD 148 6.1
Placebo 162 6.2
A negative value in the difference in adjusted change from baseline in
placebo indicates a greater improvement in patient-reported sympto
CI, confidence interval; PAC-SYM, patient assessment of constipation
SE, standard error.
* P value of comparison of each methylnaltrexone dose group against plac 0.05) (Table 4). For rectal symptoms and stool symptoms,
tatistically significant improvements compared with placebo
ere detected in the methylnaltrexone QD group (P  0.001)
nd the methylnaltrexone QOD group (P 0.05) (Table 4). Sim-
lar to Day 14, there were no statistically significant differ-
nces in the change from baseline scores between the meth-
lnaltrexone QD and QOD dosing arms and placebo in
bdominal symptom and pain intensity scores at the end of
he double-blind period (Table 4). The analyses with the ob-
erved case data on Day 14 and Day 28 showed similar signif-
cant test results as reported above with the LOCF method
xcept for the PAC-SYM global score on Day 14 in the meth-
lnaltrexone QOD group, which showed a statistically signifi-
ant (P  0.05) greater improvement from baseline compared
o placebo in the observed case analyses.
On Day 28, 53% of patients in the methylnaltrexone QD
rm, 52% in the methylnaltrexone QOD arm, and 41% in the
lacebo arm demonstrated at least 0.5 point improvement




1.73 (0.78) 1.60 (0.85)
1.31 (0.90) 1.23 (0.89)
2.28 (0.93) 2.30 (0.88)
1.85 (0.73) 1.80 (0.70)
6.26 (1.93) 6.33 (1.72)
QOD, every other day.








D) Mean (SD) Mean (SE) Mean (95% CI) P value*
8) 0.38 (0.74) 0.35 (0.05) 0.02 (0.13, 0.16) 0.825
5) 0.27 (0.65) 0.26 (0.05) 0.11 (0.04, 0.25) 0.141
6) 0.32 (0.78) 0.36 (0.05)
8) 0.56 (0.88) 0.51 (0.05) 0.30 (0.45, 0.15) 0.001
0) 0.40 (0.70) 0.41 (0.05) 0.20 (0.35, 0.05) 0.009
7) 0.17 (0.68) 0.21 (0.05)
2) 0.74 (0.98) 0.75 (0.07) 0.40 (0.58, 0.21) 0.001
9) 0.56 (0.88) 0.56 (0.07) 0.20 (0.38, 0.02) 0.030
4) 0.36 (0.81) 0.36 (0.06)
0) 0.58 (0.70) 0.56 (0.05) 0.24 (0.37, 0.11) 0.001
6) 0.42 (0.60) 0.42 (0.05) 0.10 (0.23, 0.03) 0.134
4) 0.30 (0.61) 0.32 (0.05)
0) 0.00 (1.59) 0.02 (0.11) 0.07 (0.24, 0.38) 0.665
9) 0.07 (1.45) 0.08 (0.11) 0.01 (0.30, 0.32) 0.958
3) 0.10 (1.37) 0.08 (0.11)
-SYM domain and total scores between methylnaltrexone group and
the methylnaltrexone arm.



















































































181V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 7 7 – 1 8 3linical improvement criteria. Similarly approximately 29% of
atients in the methylnaltrexone QD arm, 18% in the meth-
lnaltrexone QOD arm, and 17% in the placebo demonstrated
oderate clinical improvement with at least a 1 point im-
rovement from baseline on the global score.
afety
he three most commonly reported adverse events (AEs) were
bdominal pain, diarrhea, and nausea. In the methylnaltrex-
ne 12 mg QD treatment group (N150), the rates were 19.3%
or abdominal pain, 6.0% for diarrhea, and 8.7% for nausea and
ere similar to those reported in the methylnaltrexone 12 mg
OD group (N148): 15.5%, 11.5%, and 11.5%, respectively.
hese rates were higher than those reported in the placebo
roup (N162): 3.7%, 3.7%, and 6.2%, respectively.
The most common AEs leading to withdrawal were abdomi-
al pain and nausea. Eight patients withdrew due to abdominal
ain (n 3 in the 12 mg QD group; n 5 in the 12 mg QOD group),
due to abdominal distension (n 1 in the 12 mg QD group; n
in the 12 mg QOD group), and 6 due to nausea (n 2 in the 12
g QD group; n 4 in the 12 mg QOD group). Protocol violations
ccounted for 4.6% of the early withdrawals (n 8 in the 12 mg
D group; n 7 in the 12 mg QOD group, and n 6 in placebo).
iscussion
lthough recognized as the cornerstone of treatment for can-
er-related pain, opioid therapy also represents an important
herapeutic option for relief of moderate to severe non-malig-
ant pain [19]. Successful pain management with opioids re-
uires that adequate analgesia be achieved without excessive
ide effects like constipation. Current laxative therapy for OIC,
Table 4 – PAC-SYM and pain scores and change from base
Construct Treatment N
Me
Abdominal symptoms Methylnaltrexone 12 mg QD 150 1.2
Methylnaltrexone 12 mg QOD 148 1.3
Placebo 162 1.2
Rectal symptoms Methylnaltrexone 12 mg QD 150 0.8
Methylnaltrexone 12 mg QOD 148 0.8
Placebo 162 0.9
Stool symptoms Methylnaltrexone 12 mg QD 150 1.5
Methylnaltrexone 12 mg QOD 148 1.5
Placebo 162 1.8
Global score Methylnaltrexone 12 mg QD 150 1.2
Methylnaltrexone 12 mg QOD 148 1.3
Placebo 162 1.4
Pain score Methylnaltrexone 12 mg QD 149 6.0
Methylnaltrexone 12 mg QOD 148 5.9
Placebo 162 6.2
A negative value in the difference in adjusted change from baseline
constipation symptoms in the methylnaltrexone arm compared with
CI, confidence interval; PAC-SYM, patient assessment of constipation
SE, standard error.
* P value of comparison of each methylnaltrexone dose group againsven optimally titrated, may be burdensome or ineffective for Pome patients. A recent survey of patients taking oral opioids
nd laxatives found that opioid-induced bowel dysfunction
OBD) can compromise pain control: one-third of patients had
issed, decreased, or stopped using opioids to ease having a
owel movement [20]. Furthermore, 92% of patients who had
ecreased or stopped using opioids due to OBD reported in-
reased pain after doing so, resulting in negative effects on
uality of life and activities of daily living. Opioid antagonists
uch as naloxone can cross the blood–brain barrier, resulting
n pain and opioid withdrawal [7,21]. In contrast, methylnal-
rexone belongs to a new drug class with selective antagonism
f peripheral mu-opioid receptors and might help relieve OIC
ut maintain analgesia [7,22]. Thus, methylnaltrexone SC may
ddress an unmet need in the management of chronic pain by
reating OIC without diminishing analgesia.
Optimal pain management requires inclusion of the pa-
ient’s perspective during treatment. Achieving optimal anal-
esia, while minimizing constipation, requires the accurate
nd standardized assessment of constipation symptoms with
ymptom evaluation and management over time [18]. One in-
trument used in this study to obtain patient’s perspective was
he PAC-SYM questionnaire, which has been demonstrated and
ocumented to be a sensitive, reliable, valid, and responsive
easure for assessing the symptoms of OIC [18]. Assessment
ith the PAC-SYM included symptoms of rectal bleeding, dis-
omfort or bloating in the stomach, stool appearance, and
hether the bowel movement felt “complete.” The symptoms
re among those that patients associate with OIC [5,23–25].
In this study, patients in both the methylnaltrexone QD
nd QOD groups showed significant improvements in several
AC-SYM domains compared with placebo as early as the first
ssessment on treatment on Day 14, and these were main-








D) Mean (SD) Mean (SE) Mean (95% CI) P value*
2) 0.50 (0.85) 0.47 (0.06) 0.12 (0.27, 0.04) 0.135
3) 0.36 (0.66) 0.35 (0.06) 0.00 (0.15, 0.15) 0.996
5) 0.31 (0.81) 0.35 (0.05)
6) 0.62 (0.98) 0.56 (0.06) 0.26 (0.42, 0.11) 0.001
1) 0.45 (0.68) 0.46 (0.06) 0.16 (0.32, 0.00) 0.050
4) 0.25 (0.79) 0.30 (0.06)
4) 0.75 (1.03) 0.76 (0.07) 0.33 (0.51, 0.14) 0.001
7) 0.69 (0.85) 0.69 (0.07) 0.26 (0.45, 0.07) 0.008
8) 0.44 (0.92) 0.43 (0.07)
1) 0.63 (0.78) 0.62 (0.05) 0.25 (0.39, 0.10) 0.001
8) 0.52 (0.61) 0.52 (0.05) 0.15 (0.29, 0.01) 0.040
5) 0.35 (0.68) 0.37 (0.05)
6) 0.14 (1.62) 0.16 (0.13) 0.09 (0.43, 0.25) 0.610
0) 0.30 (1.55) 0.30 (0.13) 0.23 (0.57, 0.11) 0.182
4) 0.09 (1.75) 0.07 (0.12)
C-SYM domain and total scores indicates a greater improvement in
ebo.





























































































































182 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 7 7 – 1 8 3ere statistically significant at Day 28. Improvements in sub-
cale scores for stool symptoms indicate favorable outcomes
n one or more of the symptoms including straining, hard
tools and a feeling of incomplete evacuation. Activation of
he mu-opioid receptor within the bowel wall interferes with
ormal tone and contractility, delaying transit time of the fe-
al contents [26]. Increased contractions of circular muscles
ause non-propulsive kneading and churning, increasing fluid
bsorption, which dries and hardens the stool. At the same
ime, longitudinal propulsive peristalsis is decreased, provid-
ng additional time for drying of the stool, ultimately resulting
n reduced frequency of bowel movements, formation of hard
tools, straining, incomplete evacuation of bowel, and sensa-
ion of anorectal bowel obstruction [5,27,28]. As a peripheral
u-opioid receptor antagonist, methylnaltrexone has the po-
ential to block opioid actions mediated by peripheral opioid
eceptors and thus relieve the associated stool symptoms. The
esults of our study confirm that in addition to improving fre-
uency of bowel movements, methylnaltrexone has a signifi-
ant effect on the stool symptoms associated with opioid-in-
uced constipation.
Significant improvements in rectal symptoms (including
hanges in painful defecation, rectal burning, and bleeding)
ere observed as early as Day 14 in patients treated daily with
ethylnaltrexone and persisted until Day 28. Activation of
u-opioid receptors increases anal sphincter tone; hence, re-
exive relaxation in response to rectal distension is reduced
nd defecation becomes more difficult and painful [5,26,27].
hus methylnaltrexone may be able to improve anorectal dys-
unction associated with opioids and alleviate rectal symp-
oms as seen in the results of our study.
We observed no statistical differences in the change from
aseline at Day 14 or Day 28 in abdominal symptoms scores
etween the methylnaltrexone QD and QOD dosing arms and
lacebo despite the fact that abdominal pain is the most com-
only reported AE in this study population. We note that AEs
xperienced by both treatment groups were primarily gastro-
ntestinal events, consistent with reports for other drugs ad-
inistered for the treatment of chronic constipation [24,29].
bdominal pain was also commonly reported as an adverse
vent in previous methylnaltrexone clinical studies of pa-
ients with advanced illness [7,22].
Overall, the response to treatment with methylnaltrexone
C of patients having OIC related to chronic non-malignant
ain as assessed by the PAC-SYM questionnaire was consis-
ent with the primary end point results of this study [14]. In
ontrast to the improvement demonstrated by the primary
nd points, which were based on daily assessments at 4 hours
r at 24-hours post dose, the PAC-SYM responses reported
ere provide evidence of improvement over 28 days, which
ay better reflect long-term change in constipation symp-
oms for patients on chronic therapy of opioids. The short
uration of treatment is a limitation of the study.
We observed no statistical differences in the change from
aseline on Day 14 or Day 28 in pain intensity scores between
he methylnaltrexone QD and QOD dosing arms and placebo
hus suggesting that methylnaltrexone decreases the consti-
ating effects of opioids without affecting centrally mediated
nalgesia. By adding an alkyl-substituent on the nitrogen atom af a tertiary opioid antagonist, quaternary opioid antagonists
ere designed with relatively greater polarity and less lipid sol-
bility than the parent compound. Due to its quaternary ammo-
ium structure, N-methylnaltrexone has very little permeability
f the blood-brain barrier. This structure should have little effect
n central opioid receptor binding [30].
Previous studies of methylnaltrexone therapy of patients
ith advanced illness and OIC showed a favorable impact on
atient-reported constipation distress and Global Clinical Im-
rovement of Change (GCIC) in bowel status scores [22,31].
ur study measured constipation symptoms from a broader
erspective using the PAC-SYM, a validated multi-item instru-
ent to assess constipation symptoms with a change of ap-
roximately half a point corresponding to minimal clinical
mprovement and changes of about 1 point corresponding to
oderate clinical improvement [17]. Our study results showed
hat at the end of the double-blind period, approximately 53%
f patients in each of the methylnaltrexone arms met the min-
mal improvement criteria compared to approximately 41% in
he placebo group. About one-third of the patients (29%) in the
ethylnaltrexone QD arm met the criteria for moderate clin-
cal improvement compared to 18% and 17% in the methyl-
altrexone QOD arm and placebo groups, respectively.
It is important to acknowledge the potential limitations of
he study. First, the trial’s limited duration (4-week, double-
lind period) does not reflect the nature of the management of
IC in chronic, non-malignant pain. The median duration of
IC in our patient population was more than 58 months,
hich speaks to the need for studies providing evidence of
aintenance of the efficacy observed at 4 weeks over a longer
ime period. Second, patients enrolled were not expected to
equire further titration of their opioid dosage; however, in
linical practice, exacerbations of pain may necessitate up-
ard opioid titration. In addition, the population studied was
imited to North America and additional studies may be re-
uired in other regions.
onclusion
espite these limitations, the results of our study indicate
linically meaningful improvement in constipation symp-
oms over 1 month of treatment without a significant effect on
ain intensity scores. This improvement, based on patient as-
essment, is of relevance in the management of OIC in clinical
ractice and complements the efficacy based on bowel move-
ent response rates [14]. In conclusion, a significant improve-
ent in patient-reported constipation symptoms was demon-
trated with methylnaltrexone SC therapy with QD or QOD
osing in patients with chronic non-malignant pain and OIC
ithout affecting centrally mediated analgesia.
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